|
|
Vaccine Detail
|
FMP012 with AS01B adjuvant system |
| Vaccine Information |
- Vaccine Name: FMP012 with AS01B adjuvant system
- Target Pathogen: Plasmodium spp.
- Target Disease: Malaria
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Antigen: FMP012: Escherichia coli-expressed P. falciparum cell-traversal protein for ookinetes and sporozoites (PfCelTOS) (Bennett et al., 2014)
- pfCelTOS
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
|
Human Response
- Host age: 18-50 years old (Bennett et al., 2014)
- Vaccination Protocol: Phase 1, non-randomized study
Participants were randomly assigned in 2 groups: 1). 10 µg FMP012 antigen reconstituted with 500 µL AS01B adjuvant to equal 0.5 mL final volume. Doses administered intramuscular at week 0, 4, 8, and 24. and 2). 30 µg FMP012 antigen reconstituted with 500 µL AS01B adjuvant to equal 0.5 mL final volume. Doses administered intramuscular at week 2, 6, 10, and 24. (Bennett et al., 2014)
|
| References |
Bennett et al., 2014: Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) to Evaluate the Safety and Efficacy of the Plasmodium Falciparum Vaccine Candidate FMP012 Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Naïve Adults [https://clinicaltrials.gov/ct2/show/NCT02174978?term=vaccine&cond=malaria&draw=2&rank=32]
|
|
